DFTX is trading at $42.95 (4.1% down) as investors digest the impact of a large, upsized equity raise following its recent clinical rally.

  • The company closed an $805 million public offering priced at $34.00 per share, which included the full exercise of the underwriters’ option.
  • Shares are facing short-term pressure as the market absorbs the new supply and weighs the resulting dilution against recent gains driven by positive Phase 3 trial data.